Infinium PharmachemShare price, financial results, shareholding and management
- Market cap
- ₹464 cr
- Stock P/E
- 33.2peers 15.1
- Book value
- ₹77.6
- Price to book
- 3.84
- EV / operating profit
- 19.8
- Market cap to sales
- 2.44
- ROCE · FY26
- 14.9%
- ROE · FY26
- 12.1%
- ROE, 3-year average
- 17.1%
- Operating margin · FY26
- 11.0%peers 8.9%
- Sales growth, 3 years
- 18.6%
- Profit growth, 3 years
- 11.9%
- Debt to equity
- 0.00peers 0.48
- Borrowings
- ₹0 cr
- Interest cover
- 7.0×
- Cash from business / op. profit
- 155%
- Debtor days
- 60
- Pledged
- 0.00%
- Promoter holding
- 64.91%
- Change in promoter holding
- +5.00 pts
- Shareholders
- 1,061
- 52-week high / low
- ₹325 / ₹189
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
Infinium Pharmachem share price chart
Close on 19 Nov 2026 · -3.53% on the day · Vol 7,500
Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 19 Nov 2026
- 1 month
- +1.1%
- 3 months
- +35.5%
- 6 months
- +41.3%
- 1 year
- +21.9%
- Traded a day, 20 days
- ₹0.23 cr
- Taken for delivery
- 92%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +22% | +72% |
| 3 years, a year | +19% | +12% |
| Latest half, H2 FY26 | +45% | +167% |
About Infinium Pharmachem: business, products and customers
Infinium Pharmachem makes chemicals from iodine that drug companies use to make medicines, and has started making raw materials for the dyes used in medical scans. Its plant is in Gujarat and its shares trade on NSE Emerge.
The company was formed in 2003 at Anand, Gujarat, and makes more than 220 iodine derivatives and 19 active pharmaceutical ingredients at GIDC Sojitra. Much of the work is made to order under confidentiality agreements for drug makers, a contract research and manufacturing model, and the company has named Sun Pharma, Dr. Reddy's, Glenmark, Neuland and Hetero Drugs among its customers. China and Japan are its main markets abroad, and an exclusive five-year distribution deal with K Sakai & Company covers Japan.
Iodine is all imported and makes up about 52% to 60% of what the company spends on materials, so its margin is the spread between the iodine price and what customers pay for the finished derivative. The group figures also include Infinium Healthcare, a 51% held company that trades pharma raw materials, and Shanghai Tajilin, a 51% held distributor in China, which is why consolidated sales are larger than the plant's own. The plant can make far more than it does, so higher volume would spread fixed costs over more tonnes.
Read more about the business
In January 2026 the company commissioned a new unit at Sojitra to make raw materials for contrast media, the iodine based dyes injected before X-ray and CT scans, including a compound called ATIPA. Through Infinium Healthcare it has a joint venture with IBL Elements in Texas to extract iodine from oilfield brine, from which it expects to take about 120 tonnes a year once production starts.
Management has named Samrat Pharmachem as the one listed company making iodine derivatives in India, with Calibre and G. Amphray among other makers. Blue Jet Healthcare, also listed, makes contrast media intermediates; management has said Infinium aims to supply contrast media raw materials rather than the contrast media drugs themselves.
From the offer document, the annual report for FY26, the investor presentation of November 2025, the results calls of March and June 2024 and the press release of January 2026.
Read the deeper study ↓In its favour
- It brings in more cash than it shows as profit: ₹34 cr against ₹14 cr in FY26.
- It has little debt for its size: debt to equity 0.00.
- The promoters own a large part of the company: 64.91%.
To watch
- Sales from the contrast media unit started in January 2026, aimed at about ₹100 cr a year within three years (Press release, 16 January 2026, p.2).
- Start of iodine supply from the Texas joint venture, expected by December 2026 (Investor presentation, November 2025, p.15).
- Whether the largest customer's share of sales keeps rising (Annual report FY26, p.75).
- Environmental compliance at Sojitra after the 2026 closure order (Annual report FY26, p.63).
- The promoters' share has come down: 64.91%, from 73.05%.
From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.
Infinium Pharmachem revenue and profit growth
Half-yearly results · Profit and lossSales have grown steadily. Last year profit grew faster than sales, so the company kept more from each rupee of sales.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.
Infinium Pharmachem half-yearly results
SME companies report every six months · ₹ crore
| H1FY23 | H1FY24 | H2FY24 | H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|---|---|---|
| Sales | 79 | 61 | 74 | 83 | 73 | 84.05 | 106 |
| Expenses | 71 | 51 | 66 | 75 | 65 | 73.61 | 94 |
| Operating profit | 9 | 10 | 8 | 8 | 8 | 10.44 | 11 |
| OPM | 11.0% | 17.0% | 11.0% | 10.0% | 11.0% | 12.4% | 11.0% |
| Interest | 1 | 1 | 1 | 2 | 2 | 1.56 | 1 |
| Depreciation | 0 | 1 | 1 | 2 | 2 | 1.55 | 2 |
| Profit before tax | 8 | 8 | 7 | 6 | 5 | 8.33 | 10 |
| Net profit | 6 | 6 | 5 | 5 | 3 | 5.60 | 8 |
Infinium Pharmachem profit and loss
Full years to March, FY20 to FY26 · ₹ crore, consolidated where reported
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Sales | 39 | 71 | 99 | 114 | 136 | 155.71 | 190 |
| Expenses | 36 | 66 | 89 | 98 | 117 | 139.29 | 168 |
| Operating profit | 2 | 5 | 10 | 16 | 19 | 16.42 | 22 |
| OPM | 6.0% | 7.0% | 10.0% | 14.0% | 14.0% | 10.6% | 11.0% |
| Other income | 1 | 1 | 1 | 1 | 2 | 2.12 | 2 |
| Interest | 1 | 1 | 2 | 3 | 2 | 3.67 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 3 | 3.29 | 3 |
| Exceptional and other items | · | · | 1 | · | -1 | · | · |
| Profit before tax | 1 | 4 | 9 | 13 | 15 | 11.57 | 18 |
| Tax rate | 0.0% | 25.0% | 22.2% | 23.1% | 20.0% | 29.6% | 22.2% |
| Net profit | 1 | 3 | 7 | 10 | 12 | 8.15 | 14 |
| EPS ₹ | 4.65 | 13.60 | 30.55 | 9.30 | 8.12 | 5.60 | 7.80 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.
Infinium Pharmachem profitability
Margins and returns on capitalLast year the company kept about as much from each rupee of sales as the year before. It earns a moderate return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Operating margin | 6.0% | 7.0% | 10.0% | 14.0% | 14.0% | 10.6% | 11.0% |
| Tax rate | 0.0% | 25.0% | 22.2% | 23.1% | 20.0% | 29.6% | 22.2% |
| ROCE | · | 32.3% | 40.7% | 36.8% | 28.1% | 13.2% | 14.9% |
| ROE | · | 54.5% | 70.0% | 57.1% | 29.6% | 9.7% | 12.1% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Infinium Pharmachem debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown. It has almost no borrowings. Last year the business brought in more cash than it showed as profit. Customers take about as long to pay as they did in FY24.
Bars below the line are cash going out.
Infinium Pharmachem balance sheet
At each 31 March · ₹ crore
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 5 | 14 | 15.58 | 16 |
| Reserves | 3 | 6 | 12 | 17 | 45 | 93.88 | 105 |
| Net worth | 4 | 7 | 13 | 22 | 59 | 109.46 | 121 |
| Borrowings | 9 | 11 | 23 | 29 | 11 | 51.85 | 0 |
| Other liabilities | 9 | 16 | 23 | 20 | 15 | 37.08 | 54 |
| Total liabilities | 22 | 34 | 59 | 71 | 85 | 198.39 | 175 |
| Fixed assets | 4 | 5 | 4 | 19 | 20 | 24.16 | 23 |
| Capital work in progress | 0 | 4 | 8 | 0 | 0 | 1 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 | 29.02 | 29 |
| Other assets | 18 | 25 | 47 | 52 | 65 | 144.21 | 115 |
| Receivables | · | · | · | · | · | 33.75 | 31.46 |
| Inventory | · | · | · | · | · | 44.25 | 39.05 |
| Cash | · | · | · | · | · | 34.84 | 29.78 |
| Trade payables | · | · | · | · | · | 12.39 | 4.07 |
Infinium Pharmachem cash flow
₹ crore
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Cash from operations | 3 | 7 | 12 | 9 | -13 | -29.16 | 34 |
| Cash from investing | -1 | -5 | -7 | -5 | -4 | -27.21 | -7 |
| Cash from financing | -1 | -1 | -2 | -3 | 23 | 79.29 | -32 |
| Net cash flow | 1 | 1 | 3 | 1 | 6 | 22.92 | -5 |
| Capital spending | · | · | · | · | · | 8.65 | 9.69 |
Working capital
Days
| FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 75 | 59 | 57 | 49 | 55 | 79 | 60 |
| Inventory days | 84 | 62 | 78 | 89 | 87 | 137 | 96 |
| Days payable | 82 | 79 | 56 | 31 | 16 | 38 | 10 |
| Cash conversion cycle | 76 | 43 | 78 | 108 | 126 | 178 | 146 |
| Working capital days | 46 | 12 | 25 | 27 | 96 | 97 | 99 |
Infinium Pharmachem peers and competitors
Listed SME companies in the same industryBy sales, Infinium Pharmachem is number 4 of the 34 listed SME companies in pharmaceuticals & biotechnology.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Sat Kartar Life | 220 | 12.9 | 201 | 17 | 12.0% | 0.03 |
| Infinium Pharmachem | 464 | 33.2 | 190 | 14 | 11.0% | 0.00 |
| Zenith Drugs | 68 | 17.2 | 171 | 3.9 | 7.1% | 0.75 |
| Mono Pharmacare | 16 | 44.6 | 166 | 0.4 | 2.4% | 1.79 |
| Astonea Labs | 341 | 68.1 | 148 | 5 | 9.0% | 0.74 |
| Influx Healthtech | 632 | 30.8 | 147 | 20.5 | 20.3% | 0.00 |
| Jfl Life Sciences | 35 | 5.5 | 131 | 6.4 | 8.9% | 0.47 |
| Dipna Pharmachem | 11 | 3.5 | 129 | 3 | 3.9% | 0.21 |
| Trident Lifeline | 481 | 25.3 | 129 | 19 | 22.0% | 0.73 |
| Chandra Bhagat Pharma | 32 | 10.5 | 116 | 3 | 3.3% | 0.50 |
| Quest Laboratories | 154 | 10.3 | 112 | 15 | 16.3% | 0.08 |
| Median of the 10 others | 111 | 15.1 | 139 | 5.7 | 8.9% | 0.48 |
Infinium Pharmachem shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company, a little less than in the first filing shown. Big foreign and Indian funds own very little. The number of shareholders has grown a lot.
Infinium Pharmachem shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Sep 23 | Mar 24 | Sep 24 | Nov 24 | Mar 25 | Sep 25 | Mar 26 | |
|---|---|---|---|---|---|---|---|
| Promoters | 73.05% | 73.05% | 73.05% | 65.24% | 65.24% | 59.91% | 64.91% |
| Foreign investors (FIIs) | 0.00% | 0.00% | 0.00% | - | 0.00% | - | - |
| Indian institutions (DIIs) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.02% | 0.21% |
| HNIs (over ₹2 lakh each) | 9.59% | 10.19% | 9.73% | 9.65% | 18.02% | 23.02% | 18.08% |
| Small holders (up to ₹2 lakh) | 14.37% | 13.65% | 14.24% | 22.40% | 13.98% | 14.19% | 13.88% |
| Companies and others | 2.99% | 3.11% | 2.98% | 2.71% | 2.76% | 2.86% | 2.92% |
| Number of shareholders | 646 | 771 | 947 | 998 | 958 | 1,052 | 1,061 |
The named holders are at 31 March 2026, beside 30 Sept 2025, each under the group the pattern files them in.
Infinium Pharmachem study: the business from its own documents
Read from 12 of the company's own documentsInfinium Pharmachem so far
From the company's own record
- 17 April 2023Listed on NSE Emerge
- 31 March 2026Promoters at 64.91%
- 3 Oct 2024Highest close since listing, ₹358.74
Infinium Pharmachem key facts from the filings
Each figure with the document it comes from
- Largest customer
- 48.71%
- Share of FY26 standalone revenue from the single largest customer, up from 43.04%; the top five gave 71.93%.Annual report FY26, p.75
- Plant capacity
- 1,800 tonnes a year
- Installed capacity for iodine derivatives, against 293 tonnes actually made, about a fifth of what the plant can do.Investor presentation, November 2025, p.5 and p.18
- Iodine cost
- 52% to 60%
- Share of total material buying spent on iodine, which India fully imports.Transcript, June 2024 call, p.10
- Contrast media unit
- 16 January 2026
- Date the new unit for contrast media raw materials started, after a planned finish of December 2025.Press release, 16 January 2026, p.2; Investor presentation, November 2025, p.13
- Export sales
- ₹35.5 cr
- Standalone exports in FY26, down from ₹38.6 cr in FY25, while domestic sales rose.Annual report FY26, p.75
Show 5 more facts
- Plant closure
- 13 April to 20 May 2026
- The Gujarat Pollution Control Board ordered the Sojitra plant shut over alleged environmental lapses, then revoked the order; the company says it served demand from stock.Annual report FY26, p.21 and p.63
- EU approvals
- 16 products
- Products registered under EU REACH, with one more pending; FDA India also approved making APIs at the existing plant.Investor presentation, November 2025, p.12 and p.20
- Japan distributor
- 5 years
- K Sakai & Company will market all its iodine derivatives in Japan exclusively for five years.Investor presentation, November 2025, p.20
- Iodine from Texas
- About 120 tonnes a year
- Iodine the company expects to take from the IBL Elements joint venture under a 30-year supply agreement; production was expected by December 2026.Investor presentation, November 2025, p.14 to 15
- Credit rating
- ICRA BBB (Stable)
- First rating from ICRA, assigned in September 2026 on ₹52.2 cr of bank facilities.Credit rating letter, 21 September 2026, p.1 to 2
What the company said, and what happened
The company's own statements, attributed, set against what it later reported; not newboard's estimates
The company says it targets about ₹100 crore a year of revenue from contrast media raw materials within three years of the January 2026 start, at an EBITDA margin of about 30%, which it says would lift the blended margin to about 20%. Its November 2025 presentation spoke of sustainable revenue growth of 20% a year, a 14% share of its market in three to five years, and talks with two API makers for long term supply. It expected iodine from the Texas joint venture by December 2026.
| What management said | When | What happened |
|---|---|---|
| Revenue of ₹200 cr in FY26 | Investor presentation, November 2025 | ₹189.6 cr consolidated |
| Contrast media project complete in December 2025 | Investor presentation, November 2025 | Commissioned 16 January 2026 |
Is it a good business? Six questions
Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.
Infinium Pharmachem turns imported iodine into specialised chemicals that drug makers need, mostly made to order, and earns the spread between the two.
Its weak spots are dependence on one large customer, an iodine price it does not control, a plant that runs far below capacity, and a recent pollution board closure.
AverageCan it set its own prices?It keeps a fairly steady spread over iodine, but iodine is imported and its price is set abroad.
AverageHow strong is it against rivals?Few companies make this range of iodine chemicals, but customers can turn to other makers and to imports.
WatchWho are its customers?One customer gives about half of the plant's sales, and that share has been rising.
AverageDoes it need a lot of money?The main plant is built and has room to grow, but stock and dues have climbed and new projects needed fresh funds.
AverageCan it keep finding new work?New products, markets and a contrast media line give it ways to grow, but customer numbers have not grown lately.
WatchDo good and bad years swing a lot?Demand from drug makers is steady, but iodine prices, one big customer and plant approvals can move results sharply.
Who runs Infinium Pharmachem?
Promoters, directors and officers; tap a name for the background
SVSanjaykumar Viththalbhai PatelPromoter and Managing Director · holds 10.25%
Holds a master's degree from Gujarat University and has led the company's sales and marketing in India and abroad for about 20 years; a director since the company was formed and Managing Director from October 2022 to October 2027.
Offer document, p.148 and p.159; Shareholding pattern, March 2026PBPravin Bhadabhai MadhaniPromoter and Executive Director · holds 21.66%
A graduate of Saurashtra University with a postgraduate degree from M. S. University, Vadodara and an LLB from Gujarat University. A director since the company was formed, in charge of production and regulatory matters, with 20 years of experience including three and a half years as a Mamlatdar with the Government of Gujarat.
Offer document, p.148 to 149 and p.159; Shareholding pattern, March 2026MLMitesh Lavjibhai ChikhaliyaPromoter and Executive Director · holds 4.78%
Holds a master's degree in international business from Savitribai Phule Pune University; on the board since November 2010 and handles international business, finance and accounts. The offer document records Mitesh Lavjibhai Chikhaliya as a cousin of Sanjaykumar Viththalbhai Patel.
Offer document, p.148 to 149 and p.160; Shareholding pattern, March 2026NPNilesh PatelExecutive Director (Finance)
A Company Secretary with LLB and B.Com degrees and 22 years in secretarial, finance and legal work, earlier with the GSPC Group and Torrent Power. Was CFO and Company Secretary until March 2026 and moved to Executive Director (Finance) from April 2026.
Investor presentation, November 2025, p.34; Announcement, 1 April 2026, p.1 to 2; Annual report FY26, p.3KDKunj DesaiCompany Secretary, Compliance Officer and CFO
Took over as Company Secretary and CFO from 1 April 2026; the documents read give no further background.
Annual report FY26, p.3KJKeyur Jagdishchandra ShahIndependent Director
A Company Secretary with an MBA in finance and a law degree, practising as an insolvency professional and registered valuer; on the board since October 2022.
Offer document, p.149; Investor presentation, November 2025, p.33VAVaishakhi Ambrishbhai ShuklaIndependent Director
Holds a master's degree and a law degree with 15 years of experience in corporate matters and governance.
Investor presentation, November 2025, p.33Infinium Pharmachem latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹106 cr (+45%), net profit ₹8 cr (+167%) on H2 FY25.
- Shareholding, 31 March 2026: promoters 59.91% to 64.91%.
Infinium Pharmachem announcements
59 on record, latest first; each opens the filing on the exchange
- Integrated Filing- GovernanceQuarterly Compliance for Integrated Governance for quarter ended 30.09.2026PDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
- Updates'Submission of Annual Secretarial Compliance Report for purpose of Migration from NSE Emerge to Main Board of NSE'PDF ↗
- Shareholders meetingSrutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting resultsPDF ↗
- Trading WindowClosure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF ↗
- Credit Rating- NewCredit Rating- NewPDF ↗
- Shareholders meetingSrutinizers report of Annual General Meeting held on September 17, 2026. Further, the company has informed the Exchange regarding voting resultsPDF ↗
- Shareholders meetingProceedings of Annual General Meeting held on September 17, 2026PDF ↗
- Analysts/Institutional Investor Meet/Con. Call UpdatesSchedule of meetPDF ↗
- Record Datethat Record date for the purpose of MT is 10-Sep-2026PDF ↗
- Copy of Newspaper PublicationRegarding the Notice of Postal BallotPDF ↗
- Shareholders meetingNotice of Postal BallotPDF ↗
Infinium Pharmachem annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
- Offer document ↗read
- 30 June 2024 ↗read
- 31 March 2024 ↗read
- 30 Nov 2025 ↗read
- 30 June 2024 ↗read
- 31 March 2024 ↗read
Infinium Pharmachem share split, bonus and dividends
From the corporate actions the company announces on the exchange
- Bonus issueBONUS 1:1ex-date 13 Sept 2023
Checks we ran on Infinium Pharmachem's data · 10
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- !For FY26, H2FY25, H2FY26 the exchange filing's profit lines do not add up as read, so the figures shown are from the results page instead.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (1,55,83,120 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- !Earnings per share changes basis between FY22 (₹30.55) and FY23 (₹9.30) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
- ✓Revenue and profit are reported for every year shown, FY20 to FY26.
- iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.
Questions people ask about Infinium Pharmachem
What does Infinium Pharmachem do?
Infinium Pharmachem makes chemicals from iodine that drug companies use to make medicines, and has started making raw materials for the dyes used in medical scans. Its plant is in Gujarat and its shares trade on NSE Emerge.
What is the share price of Infinium Pharmachem?
₹298 at the close on 19 Nov 2026, from the exchange's daily figures.
What is the market cap of Infinium Pharmachem?
₹464 cr at the close on 19 Nov 2026, on 1,55,83,120 shares.
What is the P/E of Infinium Pharmachem?
33.2 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).
What are Infinium Pharmachem's revenue and profit?
Revenue ₹190 cr and profit after tax ₹14 cr in FY26.
Who are the promoters of Infinium Pharmachem?
Sanjaykumar Viththalbhai Patel, Pravin Bhadabhai Madhani, Mitesh Lavjibhai Chikhaliya; promoters held 64.91% at 31 March 2026.
What is Infinium Pharmachem's website?
www.infiniumpharmachem.com
More SME companies like Infinium Pharmachem
Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.
- KRM AyurvedaKRMAYURVED · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2026Market cap ₹476 cr
- Trident LifelineTLL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹490 cr
- Astonea LabsASTONEALAB · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹431 cr
- Influx HealthtechINFLUX · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2025Market cap ₹644 cr
- Aptus PharmaAPPL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹820 cr
- Accretion NutravedaANL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹244 cr
Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2023 →
Built from 3 investor presentations, 2 earnings call transcripts, 2 annual reports, 2 credit rating notes, 1 offer document, 1 result filing, 1 press release, 59 exchange announcements, 7 shareholding patterns and 7 years of reported results. Every figure carries its source; where the documents are silent, the page says so.